Clinical Trial Update: Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib [Phase 2]

View source ↗

Summary

This Phase 2 trial update describes using circulating tumor DNA in the blood to guide which patients with HR-positive, HER2-negative metastatic breast cancer ma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)
• KISQALI (ribociclib)
• Piqray (alpelisib)

Snippet

Sponsor: UNICANCER | Conditions: Breast Cancer Stage IV | Phase 2 | Status: ACTIVE_NOT_RECRUITING